CLINICAL TRIAL: EFFECTS OF LOCAL GM-CSF IN-ADJUVANT ON DENDRITIC CELLS IN MELANO

临床试验：局部 GM-CSF 佐剂对黑色素树突状细胞的影响

• 批准号: 7718603
• 负责人: Craig Lee Slingluff
• 金额: $ 0.09万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-01 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7718603
• 关键词: Adjuvant; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Dendritic Cells; Dermis; Funding; Grant; Granulocyte-Macrophage Colony-Stimulating Factor; Infiltration; Injection of therapeutic agent; Institution; Patients; Pilot Projects; Research; Research Personnel; Resources; Sentinel; Sentinel Lymph Node; Site; Skin; Source; United States National Institutes of Health; Vaccination; Week; cytokine; design; improved; melanoma

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Vaccination efficacy against melanoma may be improved by incorporating cytokines as adjuvants. This pilot study was designed to analyze the effects of GM-CSF in-adjuvant administration on dendritic cells (DC) in the skin and sentinel lymph nodes of melanoma patients. The objectives are to determine whether:(a) maximal DC infiltration into the dermis occurs one week following administration of GM-CSF, (b) an increase in DCs at the site of injection is comprised of mature and immature DC, and (c) an increase in DC in the sentinel immunized node draining the injection site is comprised mostly of mature DC.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 针对黑色素瘤的疫苗接种效力可以通过掺入细胞因子作为佐剂来改善。 本初步研究旨在分析GM-CSF辅助给药对黑色素瘤患者皮肤和前哨淋巴结中树突状细胞（DC）的影响。 目的是确定：（a）在施用GM-CSF后一周，DC最大程度地浸润真皮，（B）注射部位的DC增加是否由成熟和未成熟DC组成，以及（c）排出注射部位的前哨免疫淋巴结中的DC增加是否主要由成熟DC组成。